MIT's Technology Review Unveils 2010 TR50 List of the World's Most Innovative Companies

MIT's Technology Review Unveils 2010 TR50 List of the World's Most Innovative Companies

February 23, 2010

MIT's Technology Review unveiled its innaugural TR50 List of the World's Most Innovative Companies today, and three Flagship portfolio companies are on it: Joule Biotechnologies, Novomer, and BIND Biosciences. See the full list.

Flagship highlighted in WSJ blog Venture Capital Dispatch for having three companies in MIT Technolgy Review TR50 Most Innovative Companies list

Flagship highlighted in WSJ blog Venture Capital Dispatch for having three companies in MIT Technolgy Review TR50 Most Innovative Companies list

March 2, 2010

The Daily Start-Up (March 2, 2020)
Wall Street Journal (blog) - Scott Austin

...Seven venture firms tied with three companies apiece: Bessemer Venture Partners, Duff Ackerman & Goodrich, Flagship Ventures, Kleiner Perkins Caufield ... Read the full post online

Noubar Afeyan to Join Anatoly Chubais of RUSNANO in MIT Sloan Event

Noubar Afeyan to Join Anatoly Chubais of RUSNANO in MIT Sloan Event

April 6, 2010

On Friday, April 9, the MIT Sloan community will welcome Anatoly Chubais, Chairman and CEO of RUSNANO. RUSNANO is Russia's state-owned nanotechnology firm and was one of several firms created in 2007 to jump-start investment in non-energy sectors. Mr. Chubais has also played an important role in the launch of the SKOLKOVO Moscow School of Management where MIT Sloan has been involved in a major collaboration. Mr.

David Berry of Flagship Ventures on Funding Advice, Investment Themes, Trends in Biofuels

David Berry of Flagship Ventures on Funding Advice, Investment Themes, Trends in Biofuels

May 12, 2010

Xconomy.com
Gregory T. Huang 5/12/10

Flagship Ventures invites scientists to shack up for the summer in Kendall Square

Flagship Ventures invites scientists to shack up for the summer in Kendall Square

May 18, 2010

Posted by Scott Kirsner
Boston.com

May 18, 2010 09:16 AM

Helicos BioSciences Corporation

Helicos BioSciences Validates Performance of True Single Molecule Sequencing

Helicos BioSciences Validates Performance of True Single Molecule Sequencing

February 8, 2008

Life Science Company Presents Data at Advances in Genome Biology and Technology Meeting

Helicos BioSciences Corporation

Helicos BioSciences Announces First Order for the Helicos™ Genetic Analysis Platform

Helicos BioSciences Announces First Order for the Helicos™ Genetic Analysis Platform

February 8, 2008

Life Science Company Continues to Define a New Category in Sequencing

Epitome Biosystems

EMD launches first bead-based multiplex assays using EpiTag™ Technology from Epitome Biosystems, Inc.

EMD launches first bead-based multiplex assays using EpiTag™ Technology from Epitome Biosystems, Inc.

February 11, 2008

Gibbstown, NJ, and Waltham, MA – EMD Chemicals, Inc. (EMD), a subsidiary of Merck KGaA, Darmstadt, Germany, and Epitome Biosystems, Inc, announced today that EMD has launched WideScreen™ EpiTag™ ERK Pathway Assays, the first wave of bead-based, multiplex assays using EpiTag™ Technology licensed from Epitome Biosystems. The new line of assays will enable researchers to make quantitative, highly multiplexed measurements of important cell targets, greatly facilitating drug discovery efforts.

BG Medicine, Inc.

BG Medicine and Copenhagen General Population Study Initiate Biomarker Discovery to Identify Individuals at High Risk of Heart Attack Within Four Years before Occurrence

BG Medicine and Copenhagen General Population Study Initiate Biomarker Discovery to Identify Individuals at High Risk of Heart Attack Within Four Years before Occurrence

February 12, 2008

WALTHAM, Mass. & COPENHAGEN, Denmark - BG Medicine today announced that it has entered into a research collaboration agreement with the Copenhagen General Population Study with the goals to discover and validate novel cardiovascular biomarkers, including those predictive of rupture of atherosclerotic plaque and myocardial infarction. The planned research, which will be conducted as part of BG Medicine’s High Risk Plaque (HRP) Initiative, will apply BG Medicine’s proprietary proteomic and metabolomic discovery platform capabilities.

Acceleron Pharma, Inc.

Acceleron Pharma Announces Global Collaboration with Celgene Corporation on ACE-011 Program for Cancer-Related Bone Loss

Acceleron Pharma Announces Global Collaboration with Celgene Corporation on ACE-011 Program for Cancer-Related Bone Loss

February 20, 2008

CAMBRIDGE, Mass. & SUMMIT, N.J.--(BUSINESS WIRE)--Acceleron Pharma, Inc. and Celgene Corporation today announced a worldwide strategic collaboration for the joint development and commercialization of ACE-011, a first-in-class, novel bone-forming compound. The collaboration combines both companies’ resources and commitment to developing products for the treatment of cancer and cancer-related bone loss. In pre-clinical and early clinical studies, this innovative compound has reported success in key biomarkers of bone formation.